Alex Rodriguez TRT: Common Misinformation About This Case

What Alex Rodriguez Actually Admitted To

Rodriguez's self-reported confession covers a narrow, specific window. In a February 9, 2009 interview with ESPN's Peter Gammons, he stated that he used a banned substance he called "boli" while playing for the Texas Rangers between 2001 and 2003. He identified it as a substance he purchased in the Dominican Republic. Subsequent reporting by Sports Illustrated, which broke the original story citing anonymous sources from a 2003 survey drug test, identified the substance as testosterone and the anabolic steroid Primobolan (methenolone).

The 2009 Confession in Detail

Rodriguez told ESPN: "When I arrived in Texas in 2001, I felt an enormous amount of pressure. I felt like I had a chance to prove myself and I wanted to prove to everyone that I was worth being one of the greatest players of all time." He framed the use as youthful poor judgment, not a prescribed medical protocol. No physician's name, no diagnosis of hypogonadism, and no therapeutic rationale were offered at any point during that interview or in his subsequent press conference at spring training.

Primobolan is not approved by the FDA for any indication in the United States. Testosterone, in contrast, is FDA-approved for male hypogonadism in several formulations. Calling Rodriguez's admitted Primobolan use "TRT" is therefore doubly inaccurate: the drug is not a TRT agent, and no therapeutic intent was ever claimed.

The 2003 Survey Test Context

The 2003 anonymous survey testing program was designed to determine whether MLB needed a formal drug-testing policy. Results were supposed to remain sealed. When those results leaked and identified Rodriguez among roughly 104 players testing positive, the legal and ethical questions centered on how the data became public, not on whether he held a medical exemption. No TUE system existed in MLB for testosterone until the Joint Drug Agreement was ratified later that same year.

The Biogenesis Suspension: A Separate Episode

The 2013-2014 suspension arose from a different set of allegations entirely. MLB's investigation of the Biogenesis of America clinic in Coral Gables, Florida, resulted in suspensions for 13 players in August 2013. Rodriguez received the longest penalty: 211 games initially (later reduced to 162 on appeal), covering the rest of the 2013 season and all of 2014.

What Biogenesis Actually Involved

Documents and witness testimony obtained by MLB linked Rodriguez to Anthony Bosch, the clinic's founder, who later cooperated with MLB investigators. Bosch reportedly supplied testosterone and human growth hormone, among other substances. Rodriguez denied the allegations publicly but did not contest the suspension after his initial appeal failed before arbitrator Fredric Horowitz in January 2014.

The substances alleged in the Biogenesis case overlap with compounds used in medically supervised TRT (testosterone) and off-label HGH protocols. That overlap feeds the misinformation. The clinical distinction is straightforward: legitimate TRT requires a physician diagnosis, a confirmed serum testosterone below the laboratory reference range, an FDA-approved formulation, and in the context of professional sports, a granted TUE. None of those conditions were documented in the public record for Rodriguez.

No TUE Was Filed or Granted

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with "classic androgen deficiency syndromes" and consistently low morning serum testosterone, typically below 300 ng/dL on two separate measurements (Bhasin et al., J Clin Endocrinol Metab, 2018). MLB's Joint Drug Agreement, in force since 2004, mirrors the World Anti-Doping Agency framework for therapeutic use exemptions. A TUE requires documentation from a treating physician and approval from the relevant governing body before use, not after a positive test.

No such exemption appears in any public filing, arbitration document, or press statement connected to either the 2003 test result or the Biogenesis suspension.

Why Online Sources Keep Getting This Wrong

The misinformation about Rodriguez and TRT follows a pattern common to celebrity health reporting. Three specific errors recur.

Error 1: Conflating Testosterone Use With TRT

Testosterone is both a controlled pharmaceutical and a performance-enhancing drug when used above physiological replacement doses. Because the molecule is identical, observers assume that any testosterone use by an athlete equals TRT. That reasoning ignores dose, intent, and medical oversight entirely.

Supraphysiologic testosterone doses, such as those associated with performance enhancement, raise serum testosterone well above the normal male range of 300 to 1,000 ng/dL (Bhasin et al., NEJM, 2001). In the NEJM dose-response trial by Bhasin et al. (2001, N=61), muscle mass and strength gains increased progressively with dose, with the largest gains at 600 mg/week of testosterone enanthate, a dose 6-to-10 times the typical TRT replacement dose of 50-100 mg/week. The clinical and biochemical profile of PED-level testosterone use differs markedly from replacement-level therapy.

Error 2: Treating an Unconfirmed Diagnosis as Established Fact

Several wellness blogs and sports commentary sites have speculated that Rodriguez "likely had low testosterone" based on his behavior, physique, or career trajectory. That speculation is inference, not diagnosis. Hypogonadism requires measurement, and no serum testosterone result from Rodriguez has ever been made public by his medical providers or by MLB.

Labeling inference as fact violates basic journalistic standards and misleads patients who are researching legitimate TRT for their own health decisions.

Error 3: Assuming Retirement-Era Wellness Content Confirms Earlier PED Use Was Medical

Since retiring in 2016, Rodriguez has appeared in content adjacent to men's health, longevity, and wellness. Some readers and commentators have reverse-engineered that association into a claim that his earlier testosterone use must therefore have been therapeutic. Post-retirement wellness interest does not retroactively transform a doping violation into a medical protocol.

A useful clinical framework for distinguishing PED use from legitimate TRT in public figures: (1) Was a diagnosis documented before use began? (2) Was an approved formulation used at a replacement dose? (3) Was a TUE granted by the relevant sports authority? (4) Has the treating physician confirmed the therapeutic intent? In Rodriguez's public record, all four answers are either "no" or "unknown." Any single "no" disqualifies the TRT label.

The Clinical Reality of TRT in Athletes

Understanding what legitimate TRT looks like helps clarify why Rodriguez's case does not fit the description.

Diagnostic Requirements

The Endocrine Society guideline specifies that a diagnosis of male hypogonadism should be based on two morning serum testosterone measurements on separate days, both below 300 ng/dL, combined with symptoms such as decreased libido, fatigue, reduced muscle mass, or erectile dysfunction (Bhasin et al., 2018). A single low value is insufficient. Symptoms alone are insufficient.

TRT Doses in Clinical Practice

Standard TRT doses range from 50 to 100 mg of testosterone cypionate or enanthate weekly, or equivalent formulations such as testosterone gel (AndroGel, 1.62%) at 20.25-81 mg/day transdermally. The goal is to raise serum testosterone to the mid-normal range, roughly 400-700 ng/dL, not to exceed it. Doses used for performance enhancement in sport are typically 300-600 mg/week or higher. That 3-to-10-fold difference in dose is not a nuance. It is a clinically defining distinction.

TUE Standards in Professional Sports

The World Anti-Doping Agency's 2024 International Standard for Therapeutic Use Exemptions requires that a TUE application demonstrate: (1) the athlete has a documented medical condition requiring prohibited substance treatment; (2) no reasonable permitted alternative exists; and (3) the therapeutic dose used would not produce performance enhancement beyond restoring normal health. MLB's independent program administrator reviews TUE applications under similar criteria. Athletes who use testosterone without a granted TUE are subject to suspension regardless of whether they believe themselves to have low testosterone.

What Rodriguez Has Said About His Health in Recent Years

Rodriguez has discussed fitness, diet, and longevity publicly in podcast appearances and social media content since retiring. He has not, in any traceable public statement reviewed for this article, claimed to be on prescribed TRT or to have received a hypogonadism diagnosis. His health-oriented content covers nutrition, training, and general wellness, categories that overlap with but do not equal TRT therapy.

Any article asserting that Rodriguez "currently takes TRT" or "has been prescribed testosterone" should be asked to supply a primary source. No such source has been identified as of the publication date of this article.

The Broader Problem: PED History Distorts TRT Conversations

Rodriguez's case is representative of a wider media failure. When a high-profile athlete's PED history is later described as "TRT," it does two things simultaneously: it minimizes the doping violation and it stigmatizes legitimate testosterone replacement therapy by associating it with cheating.

Both outcomes are harmful. Men with genuine hypogonadism who could benefit from TRT sometimes avoid treatment because they fear the social association with doping. The CDC's National Health and Nutrition Examination Survey data indicate that testosterone deficiency affects approximately 4-5 million American men, with many cases going undiagnosed and untreated (Mulligan et al., Int J Clin Pract, 2006). Stigma rooted in conflated media narratives contributes to that treatment gap.

A 2020 analysis in JAMA Internal Medicine found that direct-to-consumer advertising and media coverage of testosterone therapy substantially influenced patient and clinician perceptions of who should receive treatment, frequently decoupled from clinical criteria (Nguyen et al., JAMA Intern Med, 2020). The Rodriguez narrative, repeated without correction, functions as a species of that same distortion.

MLB Drug Policy and Testosterone: A Brief History

Context matters for evaluating Rodriguez's timeline.

Before 2003, MLB had no formal drug-testing program and no prohibition on anabolic steroids under its collective bargaining agreement. The 2002 collective bargaining agreement mandated survey testing in 2003, and the Joint Drug Agreement took effect in 2004. First-time violations drew a 10-game suspension. Penalties escalated with subsequent violations.

By 2005, following congressional pressure and the publication of the Mitchell Report in 2007, MLB tightened penalties. The Mitchell Report, commissioned by Commissioner Bud Selig and authored by former Senator George Mitchell, named 89 players and identified systemic failures in the sport's drug-control program. Rodriguez was not named in the Mitchell Report. His 2003 positive test result remained non-public until 2009.

The Biogenesis-era suspensions of 2013 represented MLB's most aggressive enforcement action to date, relying for the first time on evidence gathered from a third-party supplier rather than from direct positive tests. That investigative method was controversial but was upheld by the arbitrator. Rodriguez's 162-game suspension under that framework remains the longest ever served by an MLB player for a drug-program violation.

Key Facts for Patients Researching TRT

The Rodriguez case is not a useful reference point for men considering legitimate testosterone therapy. The following facts from the clinical literature are more relevant.

Testosterone therapy in men with confirmed hypogonadism has shown consistent improvements in sexual function, lean body mass, and mood in randomized controlled trials. The Testosterone Trials (TTrials), a coordinated set of seven trials in men 65 and older with serum testosterone below 275 ng/dL, found significant improvement in sexual function and modest improvement in physical function with testosterone gel versus placebo over 12 months (Snyder et al., NEJM, 2016). The TTrials enrolled 790 men and reported these benefits alongside a numerically higher rate of cardiovascular events in the testosterone group, though that difference did not reach statistical significance at P<0.05.

Cardiovascular risk in TRT remains an active research area. The TRAVERSE trial (N=5,204), published in NEJM in 2023, found that testosterone replacement in middle-aged and older men with hypogonadism and pre-existing cardiovascular risk did not increase major adverse cardiovascular events compared with placebo over a mean follow-up of 33 months (Lincoff et al., NEJM, 2023). That finding provides meaningful reassurance for appropriately selected patients, distinct from the cardiovascular risks associated with supraphysiologic PED-level testosterone use.

Men considering TRT should obtain two fasting morning serum testosterone measurements, a complete metabolic panel, hematocrit, PSA (for men over 40), and an LH/FSH measurement to distinguish primary from secondary hypogonadism before starting any therapy.